C6 RDC

C6 RDC is a preclinical-stage radionuclide-drug conjugate (RDC) being developed by Helix BioPharma Corporation for the treatment of CEACAM6-expressing solid tumors. The drug utilizes a nanobody-based platform to deliver a radioactive payload directly to cancer cells that overexpress carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a cell-surface protein found on various aggressive solid tumors including colorectal, pancreatic, and non-small cell lung cancers. By linking tumor antigen-specific nanobodies to radioisotopes, C6 RDC enables targeted radiotherapy, directing radiation precisely to the tumor site while minimizing exposure to healthy tissues. This candidate is part of Helix BioPharma's proprietary CEACAM6-targeting platform, which leverages AI-driven optimization to refine antibody constructs for high binding affinity and optimal manufacturing yields.

Other names

CEACAM6-radionuclide-drug conjugateCEACAM-6-radionuclide-drug conjugateCEACAM 6-radionuclide-drug conjugate